US FDA's Oncology Division Wants To Know About Your Pipeline, Not Just Your NDAs
Oncology Center of Excellence Director Richard Pazdur says agency invites sponsors to present about molecules under development to learn more about future plans.
You may also be interested in...
US FDA Commits To Meeting With Complex ANDA Sponsors, Works Hard To Avoid It
Agency willing to talk to generic sponsors about complex product issues, but it can avoid the resource-intensive process by updating product-specific development guidances.
PDUFA VII Already: Could Breakthrough Ideas Apply Outside Program?
Success of enhanced communications in particular made one stakeholder wonder whether FDA could use it with non-breakthrough applications.
FDA's Pazdur Jumps Over To New 'Moonshot' Role
Creation of agency's new Oncology Center of Excellence means the Office of Hematology and Oncology Products, often seen as FDA's model product review shop, needs new leadership – at least temporarily.